Involvement of low-density lipoprotein receptor-related protein (LRP) in the clearance of factor VIII in von Willebrand factor-deficient mice

被引:70
作者
Schwarz, HP
Lenting, PJ
Binder, B
Mihaly, J
Denis, C
Dorner, F
Turecek, PL
机构
[1] Baxter Hyland Immuno, A-1221 Vienna, Austria
[2] Univ Vienna, Vienna, Austria
[3] Harvard Univ, Ctr Blood Res, Boston, MA 02115 USA
[4] CLB, Dept Plasma Prot Technol, Amsterdam, Netherlands
关键词
D O I
10.1182/blood.V95.5.1703.005k20_1703_1708
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Factor VIII is tightly noncovalently linked to von Willebrand factor (vWF) in plasma with a stoichiometry of 1:50, and vWF deficiency results in secondary factor VIII deficiency, with accelerated clearance of factor VIII from the circulation, We used a murine model of severe von Willebrand disease (vWF knockout mice) to study the effect of a recombinant vWF/pro-vWF preparation (rpvWF) on factor VIII survival and to investigate whether low-density lipoprotein receptor-related protein (LRP) might be involved in the in vivo clearance of factor VIII in the absence of vWF, vWf deficient mice received 70 U/kg rpvWF in the first series of experiments, and in a second series, 80 mg/kg receptor-associated protein (RAP) as a recombinant fusion protein to block the action of LRP. Factor VIII levels were measured at time 0, or 1 or 3 hours after administration of rpvWF or RAP. RAP induced a sustained rise in factor VIII levels comparable to that induced by rpvWF, In a third series, the preadministration of RAP resulted in a slower disappearance of factor VIII antigen (measured by an enzyme-linked immunosorbent assay specific for human factor VIII) after infusion of recombinant factor VIII, These findings suggest that the accelerated clearance of factor VIII seen in the absence of vWF may be a result of the involvement of LRP in factor VIII metabolism. (C) 2000 by The American Society of Hematology.
引用
收藏
页码:1703 / 1708
页数:6
相关论文
共 49 条
[1]  
[Anonymous], LAB MANUAL BLOOD COA
[2]   Receptor-associated protein: a specialized chaperone and antagonist for members of the LDL receptor gene family [J].
Bu, GJ .
CURRENT OPINION IN LIPIDOLOGY, 1998, 9 (02) :149-155
[3]   Blood coagulation in hemophilia A and hemophilia C [J].
Cawthern, KM ;
van't Veer, C ;
Lock, JB ;
DiLorenzo, ME ;
Branda, RF ;
Mann, KG .
BLOOD, 1998, 91 (12) :4581-4592
[4]   A mouse model of severe von Willebrand disease:: Defects in hemostasis and thrombosis [J].
Denis, C ;
Methia, N ;
Frenette, PS ;
Rayburn, H ;
Ullman-Culleré, M ;
Hynes, RO ;
Wagner, DD .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (16) :9524-9529
[5]  
FAY PJ, 1991, J BIOL CHEM, V266, P2172
[6]   STRUCTURAL-ANALYSIS OF RECOMBINANT VON-WILLEBRAND-FACTOR - IDENTIFICATION OF HETERO-DIMERS AND HOMO-DIMERS [J].
FISCHER, B ;
MITTERER, A ;
SCHLOKAT, U ;
DENBOUWMEESTER, R ;
DORNER, F .
FEBS LETTERS, 1994, 351 (03) :345-348
[7]  
FOSTER PA, 1987, J BIOL CHEM, V262, P8443
[8]  
GILBERT GE, 1992, J BIOL CHEM, V267, P15861
[9]  
GILBERT GE, 1990, J BIOL CHEM, V265, P815
[10]   CLINICAL AND BIOLOGICAL EVALUATION IN VONWILLEBRANDS DISEASE OF A VONWILLEBRAND-FACTOR CONCENTRATE WITH LOW FACTOR-VIII ACTIVITY [J].
GOUDEMAND, J ;
MAZURIER, C ;
MAREY, A ;
CARON, C ;
COUPEZ, B ;
MIZON, P ;
GOUDEMAND, M .
BRITISH JOURNAL OF HAEMATOLOGY, 1992, 80 (02) :214-221